Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.

According to the American Cancer Society, non-small cell lung cancer is often categorized in one of two stages: limited or extensive. "If your cancer is limited stage, you might get radiation or ...

Henlius' commitment to stringent quality standards has been instrumental in achieving EC approval for serplulimab. In 2023, Henlius' manufacturing facilities and production lines of serplulimab ...

This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Serplulimab is the world's first anti-PD-1 mAb approved for first-line treatment of ES-SCLC. Underpinned by clinical needs, Henlius has carried out a differentiated and multi-dimensional layout of ...